Publications
506 results found
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on other oral antidiabetic drugs and insulin therapy: 17.5 months (95%CI: 12.8-20.9; 82 events), patients not receiving other oral diabetes medications and insulin therapy 17.8 months (95%CI: 15.4 – 19.7; 750 events). B) Progression Free Survival whole cohort; other oral diabetes medications and insulin therapy: 8.2 months (95%CI: 6.2-11.4; 106 events), patients not receiving other oral diabetes medications and insulin therapy: 8.1 months (95%CI: 7.1 – 9.2; 951 events).</p></jats:p>
Ottensmeier CHH, Pinato DJJ, Armstrong AC, et al., 2023, Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial-Report after completion of monotherapy dose-finding, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on any diabetes medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), patients not receiving diabetes medications: 17.5 months (95%CI: 14.2 – 26.6; 77 events). B) Progression Free Survival NSCLC matched cohort; patients on any diabetes medication: 7.9 months (95%CI: 5.4 – 10.8; 113 events), patients not receiving diabetes medications: 10.1 months (95%CI: 7.7 – 13.8; 99 events). C) Overall Survival Melanoma matched cohort; patients on any diabetes medication: 22.9 months (95%CI: 12.0 – NR; 25 events), patients not receiving diabetes medications: NR months (95%CI: 28.8 – NR; 52 events). D) Progression Free Survival Melanoma matched cohort; patients on any diabetes medication: 11.4 months (95%CI: 4.9 – 23.4; 37 events), patients not receiving diabetes medications: 13.8 months (95%CI: 8.7 – 26.0; 77 events). NR: not reached; PSM: propensity score matching.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), patients not receiving metformin: 19.0 months (95%CI: 16.4 – 21.1; 732 events). B) Progression Free Survival whole cohort; patients on metformin: 7.9 months (95%CI: 5.3-10.1; 124 events), patients not receiving metformin: 8.3 months (95%CI: 7.3 – 9.5; 933 events).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Scatter diagram with regression line summarizing the linear regression analysis between the median baseline glycaemia (used as independent variable: x-axes) and median baseline NLR (used as dependent variable: y-axes). 133 patients included; A significant regression equation was found F(1,131)= 4.09, p = 0.04) with an R2 of .030. NLR: neutrophil to lymphocyte ratio.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Tumour micron-environment transcriptome analysis.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Detailed random blood sugar test results used to compute the median baseline glycaemia (MBG). 133 patients included (30 from the Pascale Cancer Institute and 103 from Imperial College London Cohort.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>NSCLC cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:1, caliper 0.1).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>NSCLC cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:1, caliper 0.1).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution between patients on metformin only and those who were not on diabetes medications.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution between patients on metformin only and those who were not on diabetes medications.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution between patients on other oral antidiabetic drugs/insulin only and those who were not on diabetes medications.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:2, caliper 0.1).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics of patients included in the targeted transcriptome analysis.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:2, caliper 0.1).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Details of diabetes medications.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Participating centres’ list.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Details of diabetes medications.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Detailed random blood sugar test results used to compute the median baseline glycaemia (MBG). 133 patients included (30 from the Pascale Cancer Institute and 103 from Imperial College London Cohort.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics of patients included in the targeted transcriptome analysis.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution between patients on other oral antidiabetic drugs/insulin only and those who were not on diabetes medications.</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).</p></jats:p>
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).</p></jats:p>
D'Alessio A, Pai M, Spalding D, et al., 2023, Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Pinato DJ, Li X, Mishra-Kalyani P, et al., 2023, Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma., JHEP Reports, Vol: 5, Pages: 100747-100747, ISSN: 2589-5559
BACKGROUND & AIMS: Immune checkpoint inhibitors (ICIs) alone or in combination with other ICIs or vascular endothelial growth factor pathway inhibitors are therapeutic options in unresectable/metastatic hepatocellular carcinoma (HCC). Whether antibiotic (ATB) exposure affects outcome remains unclear. METHODS: This study retrospectively analysed an FDA database including 4,098 patients receiving ICI (n = 842) either as monotherapy (n = 258) or in combination (n = 584), tyrosine kinase inhibitor (TKI) (n = 1,968), vascular endothelial growth factor pathway inhibitors (n = 480), or placebo (n = 808) as part of nine international clinical trials. Exposure to ATB within 30 days before or after treatment initiation was correlated with overall survival (OS) and progression-free survival (PFS) across therapeutic modality before and after inverse probability of treatment weighting (IPTW). RESULTS: Of 4,098 patients with unresectable/metastatic HCC, of which 39% were of hepatitis B aetiology and 21% were of hepatitis C aetiology, 83% were males with a median age of 64 years (range 18-88), a European Collaborative Oncology Group performance status of 0 (60%), and Child-Pugh A class (98%). Overall, ATB exposure (n = 620, 15%) was associated with shorter median PFS (3.6 months in ATB-exposed vs. 4.2 months; hazard ratio [HR] 1.29; 95% CI 1.22, 1.36) and OS (8.7 months in ATB-exposed vs. 10.6 months; HR 1.36; 95% CI 1.29, 1.43). In IPTW analyses, ATB was associated with shorter PFS in patients treated with ICI (HR 1.52; 95% CI 1.34, 1.73), TKI (HR 1.29; 95% CI 1.19, 1.39), and placebo (HR 1.23; 95% CI 1.11, 1.37). Similar results were observed in IPTW analyses of OS in patients treated with ICI (HR 1.22; 95% CI 1.08, 1.38), TKI (HR 1.40; 95% CI 1.30, 1.52), and placebo (HR 1.40; 95% CI 1.25, 1.57). CONCLUSIONS: Unlike other malignancies where the detrimental effect of ATB may be more prominent in ICI recipients, ATB is associated with worse
Cortellini A, D'Alessio A, Cleary S, et al., 2023, Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
<jats:p><p>Scatter diagram with regression line summarizing the linear regression analysis between the median baseline glycaemia (used as independent variable: x-axes) and median baseline NLR (used as dependent variable: y-axes). 133 patients included; A significant regression equation was found F(1,131)= 4.09, p = 0.04) with an R2 of .030. NLR: neutrophil to lymphocyte ratio.</p></jats:p>
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.